FDA Approves BMS and J&J HIV Treatments
Bristol-Myers Squibb and Johnson & Johnson announced FDA-approval of Evotaz and Prezcobix, combination HIV-1 infection treatments.
On Jan. 29, 2015, Bristol-Myers Squibb (BMS) and Johnson & Johnson (J&J) both announced FDA approval of HIV treatments. BMS announced the approval of Evotaz (atazanavir and cobicistat) when combined with other antiretroviral agents for the treatment of the HIV-1 in adults. On the same day, J&J announced the approval of Prezcobix (darunavir and cobicistat) tablets when combined with other antiretroviral agents.
Both treatments are a once-daily tablet containing a pharmacokinetic enhancer called cobicistat produced by Gilead Sciences, however, Evotaz is combined with the protease inhibitor Reyataz (atazanavir), while Prezcobix uses the protease inhibitor darunavir. The treatments are meant for patients who have not experienced any baseline resistance to the components within the treatments.
Sources:
Bristol-Myers Squibb
Texas' MD Anderson Cancer Center Creates New Cell Therapy Institute
November 11th 2024With the launch of the Institute for Cell Therapy Discovery and Innovation, the MD Anderson Cancer Center will bring together expertise in developing cell therapies for cancer, autoimmune diseases, and infections.
